LCL161 CAS:1005342-46-0

LCL161 enhanced the pro apoptotic effect of nilotinib and PKC412 on leukemia in vitro,and enhanced the activity of two kinase inhibitors on leukemia in vivo.In addition,LCL161 synergized with nilotinib in vivo and significantly reduced the burden of leukemia to below the baseline level of inhibition of medium and high dose nilotinib.Finally,LCL161 showed antiproliferative effect on the cells with inherent resistance to tyrosine kinase inhibitors,which was the result of the mutant expression of the compound inhibitory protein target.LCL161 is a small molecule antagonist of apoptosis inhibitor(IAP),with IC50 value of 10.23 μM.lcl161 in Hep3B cells could inhibit the proliferation and activity of Hep3B and PLC5 cells.Lcl161 also had effect on ALCL cell line karpas-299 with IC50 value of 1.6μM.

msds---LCL161